New England Research & Management Inc. Buys Shares of 605 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

New England Research & Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 605 shares of the biopharmaceutical company’s stock, valued at approximately $384,000.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Savant Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 21.2% during the fourth quarter. Savant Capital LLC now owns 985 shares of the biopharmaceutical company’s stock valued at $701,000 after purchasing an additional 172 shares in the last quarter. Essex Financial Services Inc. increased its stake in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. Essex Financial Services Inc. now owns 332 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 29 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Regeneron Pharmaceuticals by 0.7% during the fourth quarter. Van ECK Associates Corp now owns 58,533 shares of the biopharmaceutical company’s stock valued at $41,694,000 after purchasing an additional 397 shares in the last quarter. Finally, Avestar Capital LLC increased its position in shares of Regeneron Pharmaceuticals by 8.9% during the fourth quarter. Avestar Capital LLC now owns 787 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 64 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of several analyst reports. Guggenheim reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research report on Monday, June 9th. The Goldman Sachs Group reduced their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research report on Thursday, April 17th. Finally, Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $836.48.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of Regeneron Pharmaceuticals stock opened at $529.24 on Friday. The company’s fifty day simple moving average is $563.19 and its 200-day simple moving average is $649.98. The stock has a market capitalization of $57.14 billion, a PE ratio of 13.83, a P/E/G ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.55 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.